Sai Parenteral's intimates delay in submitting Q3 and 9M FY26 financial results beyond April 23, 2026 deadline due to audit delays at Australian subsidiary.
Company requires extension until May 15, 2026 to compile consolidated results after receiving audited financials from Noumed Pharmaceuticals in early May.
Assures exchanges of commitment to corporate governance and plans to submit FY26 annual results by May 30, 2026 as per SEBI LODR requirements.